Everest Organics Limited launches 'Posaconazole' API

Everest Organics Limited today announced the successful development of an anti-fungal API "Posaconazole" meant to treat black fungus patients, at the lab scale in the existing R & D facility of Everest Organics Limited. Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients popularly known as Black Fungus in post Covid complications.

Dr. Srikakarlapudi Sirisha, Director, commenting on this recent development stated that "The Everest Organics Limited has successfully developed the API Posaconazole using its own in-house R&D strength at lab scale in short span of time. Further we are in advance stage of commercializing the same. Everest has successfully in near past launched and commercialized 'Oseltamivir' and 'Remdesivir' both being used for Covid19. Now we are more confident and are poised for development of more niche products in the quickest span of time because of our R&D strength.

Shares of EVEREST ORGANICS LTD. was last trading in BSE at Rs.330.5 as compared to the previous close of Rs. 335.45. The total number of shares traded during the day was 7829 in over 201 trades.

The stock hit an intraday high of Rs. 348 and intraday low of 330.5. The net turnover during the day was Rs. 2622758.

Source : Equity Bulls

Keywords